Results 101 to 110 of about 5,926 (192)

Talazoparib Regimen [PDF]

, 2020
openaire   +1 more source

Figure S1 from Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts

, 2018
Mouse Weights after treatment with talazoparib ...
Benjamin H. Lok (15008067), Elisa de Stanchina (153061), Jennifer Ma (167341), Andrew Bell (4774), John T. Poirier (10579216), James H. Laird (15022889), Charles M. Rudin (163578)   +6 more
core   +1 more source

Talazoparib and radiation enhance the senolytic efficacy of venetoclax in therapy-induced senescent triple-negative breast cancer cells

Saudi Pharmaceutical Journal
Triple-negative breast cancer (TNBC) presents ongoing clinical challenges, often leading to relapse in many patients. The relapse is partly explained by tumor cells transitioning into a senescent state following chemotherapy or radiation, resulting in a ...
Sultan Almudimeegh, Mashal M. Almutairi, Abrar Softah, Khalid Alhazzani, Lama Binobaid, Musaad Alshammari, Homood M. As Sobeai, Tareq Saleh, Moureq R. Alotaibi, Ali Alhoshani   +9 more
doaj   +1 more source

Talazoparib Tosylate [PDF]

, 2020
openaire   +1 more source

Abstract 5054: Nanoformulation of talazoparib to increase efficacy when combined with temozolomide for the treatment of Ewing sarcoma xenografts

, 2017
Ewing Family of tumors (EFT) comprises the fourth most common highly malignant childhood cancer. Although sustained event-free survival (EFS) can be achieved with intensive chemo-radiation therapy for patients with local-regional disease, this therapy is
Rostislav Likhotvorik, Srinivas Sridhar, Raushan Kurmasheva, Paige Baldwin, Nabeela Baig   +4 more
core   +1 more source

Development of capillary electrophoretic method for analysis of talazoparib

Talazoparib je noviji lijek koji se u posljednjim godinama sve više primjenjuje kod bolesnika s određenim tipovima karcinoma dojke i karcinoma prostate, a ispituje se i za druge indikacije.
Petrinac, Valentina
core   +1 more source

Exploring the role of PARP1 inhibition in enhancing antibody–drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions

Journal of Translational Medicine
Background The introduction of antibody–drug conjugates represents a significant advancement in targeted therapy of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
Andrea Ghelli Luserna di Rorà, Mouna Jandoubi, Antonella Padella, Anna Ferrari, Andrea Marranci, Cristina Mazzotti, Francesco Olimpico, Martina Ghetti, Lorenzo Ledda, Maria Teresa Bochicchio, Matteo Paganelli, Michele Zanoni, Alessandro Cafaro, Chiara Servili, Sara Galimberti, Michele Gottardi, Michela Rondoni, Mauro Endri, Daniela Onofrillo, Ernesta Audisio, Giovanni Marconi, Giorgia Simonetti, Giovanni Martinelli   +22 more
doaj   +1 more source

Development of an RP-HPLC method to evaluate the basic characteristics of talazoparib-loaded PLGA nanoparticles

The use of poly (ADP -ribose) polymerase (PARP) inhibitors for cancer treatment has been reported previously. Talazoparib is a PARP inhibitor, and its solubility problems encouraged us to prepare talazoparib-loaded poly(lactic-co-glycolic acid) (PLGA ...
Pehlivan, Sibel Bozdag, ÖNER, LEVENT, ÇELEBİER, MUSTAFA, KAPLAN, OZAN, Topcu, Beril Tas   +4 more
core   +1 more source

A REVIEW ARTICLE ON TALAZOPARIB – ANTI CANCER DRUG

Talazoparib tosylate (BMN-673, Talzenna; Pfizer) is an oral poly [ADP-ribose] polymerase (PARP) inhibitor (PARPi) that has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of germline BRCA-mutated locally advanced or metastatic breast cancer (BC). In preclinical and clinical studies,
openaire   +1 more source

Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial. [PDF]

J Pharmacokinet Pharmacodyn
Wang Y, Hadigol M, Lincha VR, Hoffman J, Azad AA, Agarwal N, Matsubara N, Zohren F, DeAnnuntis L, Wang DD.   +9 more
europepmc   +1 more source